Remarkable response of recurrent endometrial adenocarcinoma to daily oral administration of half-dose etoposide

A 71-year-old woman with right chest and left lumbar pain was referred to our hospital. Computed tomography showed multiple recurrent tumors in the abdominal cavity and bilateral lungs. She had already received several chemotherapies for the recurrent tumor, and palliative care would be appropriate. However, she was seeking another anti-cancer therapy. Therefore, she was told about low-dose etoposide therapy and consented to its administration. Treatment was very effective; serum tumor marker levels decreased dramatically, the pain was controlled, and the recurrent masses were shrinking. However, her recurrent tumor had become refractory again in the 22nd month of treatment.